Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Abbott Pays $400 Million Upfront For Reata’s Preclinical AIM Programs

Dec 12 2011

Related Content

Reata Readies Bardoxolone For Phase III Looking At Kidney Function Outcomes

Jun 24 2011

Pharmacyclic’s Co-Development Pact With Janssen Carries Largest Single-Asset Upfront Payment Of 2011

Dec 09 2011

The Abbott Split Up: Who Wins?

Oct 24 2011

Abbott Pays $450MM Up-Front For Rights To Reata's CKD Drug

Sep 23 2010

Related Companies

Abbott

Reata Pharmaceuticals, Inc.

Bristol Myers Squibb Company

Agios Pharmaceuticals, Inc.

Gilead Sciences, Inc.

Pharmasset, Inc.

Pharmacyclics, Inc.

Kyowa Kirin Co., Ltd.

Additional Topics

Europe United States Deals BioPharmaceutical

More from Europe

More from Geography

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window